NDAORALCAPSULE
Approved
Dec 2012
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
Drug data last refreshed 18h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JUXTAPID (lomitapide mesylate) is an oral small-molecule MTP inhibitor approved in 2012 for treating homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder causing severely elevated LDL cholesterol. The drug works by inhibiting microsomal triglyceride transfer protein, reducing apoB-containing lipoprotein production in the liver. It is currently in peak commercial lifecycle with 15 years of patent protection remaining.
$0.009BPart D
Peak15.0 years to LOEStable niche product with minimal competitive pressure in a rare-disease indication; small commercial team managing a specialized patient base.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
JUXTAPID careers center on managing a rare-disease product with stable but limited market size (139 Part D claims in 2023), requiring deep expertise in HoFH patient identification, physician relationships, and payer navigation. Roles emphasize quality over quantity—specialized medical knowledge and patient advocacy skills are valued more than high-volume sales execution.
Brand Manager
Worked on JUXTAPID at Chiesi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.